



Rec'd PCT/PTO 22 NOV 2004



T/KR 03/01017

RO/KR 16.09.2003
10/517355

INVESTOR IN PEOPLE

The Patent Office

Concept House
Cardiff Road

Newport
South Wales

NP10 8QQ

REC'D 29 SEP 2003

WIPO PCT

REC'D 29 SEP 2003


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

R. Mahoney

Dated 10 June 2003


PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

The
Patent
Office

23 MAY 02 0720759-9.000790
P01/7700 0.00-0211849.5

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference PA4490

2. Patent application number 0211849.5
(The Patent Office will fill in this part) 23 MAY 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames) MOK, Kenneth Hun
1 Varsity Place
John Towle Close
OXFORD
OX1 4TY
8032 9970 01
 Patents ADP number (if you know it)
 If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention IMPROVEMENTS TO RETRO-INVERSO ISOMERS

5. Name of your agent (if you have one) SOMMERVILLE & RUSHTON
45 Grosvenor Road
St Albans
Herts AL1 3AW
 Patents ADP number (if you know it) 1511001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or
 b) there is an inventor who is not named as an applicant, or
 c) any named applicant is a corporate body.
 See note (d))

NO

Patents Form 1/77

- Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 9

Claim(s) 2 *DM*

Abstract 1

Drawing(s) 1 + 1

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)


Request for substantive examination (*Patents Form 10/77*)

Any other documents
(*please specify*)

11.

I/We request the grant of a patent on the basis of this application.

Signature



Date

22 MAY 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

WHITAKER, Iain Mark
01727 854215

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

IMPROVEMENTS TO RETRO-INVERSO ISOMERS

TECHNICAL FIELD

5 The present invention involves therapeutic peptides that possess inhibitory activity towards elevation of serum triglyceride (triacylglycerol) levels, an unavoidable result that occurs upon ingestion of meals containing high composition of fat. Administration of such peptides before or concomitantly with meals allows for less net absorption of fatty acids into the system, thereby contributing to the prevention
10 of various known cardiovascular diseases as well as obesity-related ailments in general.

BACKGROUND ART

High serum triglyceride level, independent of the well-known risk factor of serum
15 cholesterol, has been regarded as an additional risk factor for developing cardiovascular diseases, including coronary heart disease (Austin MA, Am J Epidemiol 129: 249-59, 1989) and atherosclerosis (Patsch JR et al, Arterioscler Thromb 12: 1336-45, 1992). A number of pharmaceutical developments have been made to restrict the elevation of serum triglyceride levels to prevent such
20 cardiovascular ailments.

More significantly, the excessive intake of lipid with respect to energy expenditure leads to obesity, which is currently being regarded as one of the prime health concerns in the Western World. Obesity is a complex medical disorder with
25 implications for diabetes, high cholesterol, cardiovascular conditions, some forms of cancer, and is a major cause of premature mortality. Dietary restriction and behavioural changes is key to prevent obesity, however it is now becoming evident

that the success in preventing or treating obesity can be increased with pharmacotherapy. Several drugs have been developed to combat obesity, however most of these are central-nervous system (CNS)-active, and hence have high abuse potential. Therefore, it would be desirable to have a pharmaceutical agent that
5 would not have these dependency complications.

Recently, a group of low molecular weight peptides which were originally obtained and purified from a non-specific enzymatic proteolysate preparation of bovine reticulocyte protein has been shown to inhibit the elevation of serum triglyceride
10 levels (US Patent 5,958,885). The peptides isolated are low molecular weight, i.e. 3-4 residues in length, and are comprised solely of natural amino acids.

Now, retro-inverso technology, in which oligopeptides are synthesised that are similar to naturally occurring oligo-peptides but with mirror image amino acids put in
15 reverse sequence order (Chorev M, Goodman M, TIBTECH 13:438-45, 1995), is a technology that has had limited take-up in recent years. By utilising non-natural D-amino acids instead of L-amino acids, it can provide an advantage in bioavailability due to inherent resistance against various natural proteases *in vivo* but there is no expectation for its use to effectively mimic or better the biological action of naturally
20 occurring peptides.

SUMMARY OF THE INVENTION

According to a first aspect of the present invention there is provided a pharmaceutical composition for administration to a human or an animal comprising ,
25 as an active component, a peptide consisting of: D-Pro D-Tyr D-Val D-Val;
D-Pro D-Tyr D-Val; or D-Leu D-Thr D-Val.

These peptides have unexpectedly been found to have a biological activity to reduce serum triglycerides that in, the cases of D-Pro D-Tyr D-Val and D-Leu D-Thr D-Val, respectively, exceed or substantially match the activity of the corresponding natural oligo-peptide. In the case of D-Pro D-Tyr D-Val D-Val the activity is effectively double that of the natural oligo-peptide.

Unlike the natural oligopeptides, the peptides obtained from the retro-inverso chemical synthesis process are also available for functional group modifications if required. This modification further allows for greater specificity and selectivity, and will also permit to tailor the activities of the peptides to suit the patient based on his/her intake of fat composition.

The peptide may, within the scope of the claimed invention, have minor modifications of a nature that is compatible with biological systems, suitably including phosphorylation, sulphonation or iodination of the D-Tyr and / or D-Thr.

The D-Pro may, for example, be hydroxylated. Widely used automatic solid-phase peptide synthesis methods of performing this modification include N-alpha-acetylation or N-alpha-formylation for eliminating the positive charge of the N-terminus. When desiring to eliminate the negative charge on the C-terminus, a C-terminal carboxamide or alcohol ester can be readily generated by adopting standard solid-phase peptide synthesis resins.

For optimal activity, the peptide may be modified at the N or C, and suitably both, terminals of the peptide.

25

Complete reversal of ionisation state can also be straightforwardly performed. The N-terminal NH_2 group is suitably replaced with a COOH group and the C-

terminal COOH group is suitably replaced with an NH₂ group. This modification may suitably be undertaken using one of the conventional techniques for this purpose.

5 A route for this modification involves:

- (1) a C-2 substituted malonyl (or malonamyl) residue substitution for the N-terminal retro-inverso peptide residue, and
- (2) a *gem*-diamino alkyl residue substitution for the C-terminal retro-inverso peptide residue.

10

The pharmaceutical composition is suitably provided in a form selected from the group consisting of tablets, powder, granules, pills and injectable form. If provided in injectable form it is suitably selected from the group consisting of solutions, suspensions and emulsions.

15

The said injectable form may be administered by intravenous, intramuscular, subcutaneous, intracutaneous and intraperitoneal administration. The pharmaceutical composition suitably comprises from about 1 to about 100 mg of said pharmaceutical composition.

20

According to a second aspect of the invention there is suitably provided a food composition for administration to a human or an animal comprising a peptide consisting of D-Pro D-Tyr D-Val D-Val or D-Pro D-Tyr D-Val or D-Leu D-Thr D-Val as an active component.

25

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Example 1

Chemical Synthesis and Purification of Peptides

5 Peptides of the amino acid sequences shown in the sequence listing were synthesised on an Applied Biosystems/Perkin-Elmer 432A Synergy Peptide Synthesizer using FastMoc cycles. The synthesis chemistry involves 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)/piperidine activation, and uses dimethylformamide (DMF) / N-methylpyrrolidine
10 (NMP)/dimethylsulfoxide (DMSO) as the coupling solvent. Synergy Fmoc-Amide resin (Applied Biosystems/Perkin-Elmer) or Rink amide methylbenzhydrylamine (MBHA) resin (Novabiochem) was used for the solid-phase support. The constituting N- α -9-fluorenylmethoxycarbonyl (Fmoc) protected D-amino acids (N- α -Fmoc-D-proline, N- α -Fmoc-O-t-butyl-D-tyrosine, N- α -Fmoc-D-valine, N- α -Fmoc-D-
15 leucine, N- α -Fmoc-O-t-butyl-D-threonine) were from Novabiochem. The peptides were cleaved by adding 1.8 ml of trifluoroacetic acid (TFA) with 0.1 ml of 1,2-ethanedithiol (EDT) and 0.1 ml of thioanisole as scavengers for 1 hour, then precipitated with 15 ml of methyl tert-butyl ether (MTBE) at 4°C and centrifugation at
20 2000 xg. The MTBE washing was repeated three more times, and the peptides were solubilized with 20% acetic acid. To use as reference compounds, L-Val-L-Val-L-Tyr-L-Pro, L-Val-L-Tyr-L-Pro, and L-Val-L-Thr-L-Leu peptides were prepared using the same methodology.

When necessary, purification of the peptides was performed using preparative
25 reversed-phase HPLC. A Kromasil (Registered Trade Mark) KR-100-10-C8 (10 mm x 250 mm, C8, 10 μ m, 100 A, Akzo Nobel) Column was used, with a linear gradient

of 5 to 20% acetonitrile (CH_3CN) in 0.1% TFA over 20 column volumes. The fractionated peak was checked for purity using a Vydac (Registered Trade Mark) 218TP52 RP-HPLC column (2.1 mm x 250 mm, C8, 5 μm , 300 A) with a linear gradient of 1 to 25% CH_3CN in 0.1% TFA. The final purity of each peptide was greater than 97%. MALDI-TOF mass spectrometry analyses using cinnapinic acid as matrix on a Kompact Research MALDI IV instrument (Kratos Analytical) confirmed the identities of the peptides.

Example 2

10 Oral Administration of Chemically Synthesised Peptides to Determine Inhibition of Triglyceride Level Elevation After Feeding

Olive oil (10 g/kg body weight) was mixed in an emulsion with one type of peptide for each experiment, and administered orally to male ICR mice (6-week old, body weight: 25-28 g) which were fasted overnight. Blood was collected from vena cava under pentobarbital anaesthesia (60 mg/kg body weight, intraperitoneal administration) and serum triglyceride levels were determined using the Triglyceride G Test Kit (Wako Pure Chemical Industries Ltd., Japan). A dose-response curve was obtained, and the 50% inhibition dose ID_{50} were calculated. The results were compared with L-Val-L-Val-L-Tyr-L-Pro (Reference Peptide 1), L-Val-L-Tyr-L-Pro (Reference Peptide 2), and L-Val-L-Thr-L-Leu (Reference Peptide 3) and shown in Table 1.

Table 1

Peptide	ID ₅₀ (mg / mouse)
SEQ ID.No 1 (D-Pro D-Tyr D-Val D-Val)	0.016
Ref. Peptide 1(L-Val-L-Val-L-Tyr-L-Pro)	0.059
SEQ ID No 2 (D-Pro D-Tyr D-Val)	0.29
Ref. Peptide 2 (L-Val-L-Tyr-L-Pro)	0.39
SEQ ID No 3 (D-Leu D-Thr D-Val)	0.48
Ref. Peptide 3 (L-Val-L-Thr-L-Leu)	0.41

As shown in Table 1, SEQ ID NO 1 and SEQ ID NO 2 display lower ID₅₀ values and hence higher specific activities in lowering elevated triglyceride levels than Reference 1 and 2, respectively. SEQ ID NO 3, although slightly less active than Reference Peptide 3, nevertheless exhibits demonstrably similar serum triglyceride lowering activity. These findings are further reinforced by the follow-up experimental results that are summarised in Table 2 below, in which the same names are used for the peptides as above.

As noted previously, for enhanced efficacy the retro-inverso peptides suitably have modified N and C terminals, where the N-terminal of the retro-inverso peptide is converted to replace the NH₂ group with a COOH group and the C-terminal COOH group is replaced with an NH₂ group. This modification may be achieved by carrying out a C-2 substituted malonyl (or malonamyl) residue substitution for the N-terminal retro-inverso peptide residue (Residue R1 in Fig.1), and a *gem*-diamino

alkyl residue substitution for the C-terminal retro-inverso peptide residue (Residue R4).

Figure 1 shows the structural differences between the retro-inverso peptide H-D-R1-D-R2-D-R3-D-R4-OH (Structure I) and the end-group modified peptide HO-*m*R1-D-R2-D-R3-*g*R4-H (Structure II, where *m* and *g* denote malonyl and *gem*-diaminoalkyl residues, respectively).

Procedures to accomplish these end group modifications are well-documented, and are reviewed in Fletcher MD, Campbell MM, Chem Rev 1998, 98: 763-795 and Choren M, Goodman M, Acc Chem Res 1993, 26:266-73.

According to the present invention, it becomes possible to prevent hyperlipemia in human and domestic animals upon administration of the peptides found in the sequence listing. Such treatment is now known to have far reaching benefits, including but not restricted to, cardiovascular ailments such as hypertension and arteriosclerosis, and obesity-related complications in general.

Table 2

	Peptide Dosage (mg / mouse)	Serum Triglyceride (mg / 100 ml)					
Distilled Water Only	-	47					
Olive Oil Only	-	511					
Olive Oil + Peptide		SEQ ID No 1	Ref. Peptide 1	SEQ ID No 2	Ref. Peptide 2	SEQ ID No 3	Ref. Peptide 3
	0.005	490	506	510	521	488	522
	0.01	274	395	490	458	477	487
	0.02	218	386	456	472	486	456
	0.05	143	291	411	444	464	457
	0.1	112	199	365	381	372	404
	0.2	57	113	296	353	347	312
	0.4	64	28	201	239	262	222
	0.6	60	63	145	215	239	209
	0.8	55	50	62	161	203	163

CLAIMS

1. A pharmaceutical composition for administration to a human or an animal comprising a peptide consisting of D-Pro D-Tyr D-Val D-Val or D-Pro D-Tyr D-Val or
5 D-Leu D-Thr D-Val as an active component.
2. The pharmaceutical composition of claim 1 being selected from the group consisting of tablets, powder, granules, pills and injectable form.
- 10 3. The pharmaceutical composition of claim 2 which is an injectable form.
4. The pharmaceutical composition of claim 3 wherein said injectable form is selected from the group consisting of solutions, suspensions and emulsions.
- 15 5. The pharmaceutical composition of claim 3 wherein said injectable form may be administered by intravenous, intramuscular, subcutaneous, intracutaneous and intraperitoneal administration.
6. The pharmaceutical composition of claim 1 wherein the composition
20 comprises from about 1 to about 100 mg of said peptide.
7. A food composition for administration to a human or an animal comprising a peptide consisting of D-Pro D-Tyr D-Val D-Val or D-Pro D-Tyr D-Val or D-Leu D-Thr D-Val as an active component.

8. A pharmaceutical composition as claimed in any of claims 1 to 6, wherein the N-terminal NH_2 group is replaced with a COOH group and / or the C-terminal COOH group is replaced with an NH_2 group.

ABSTRACT


RETRO-INVERSO ISOMERS

5


In a first aspect the present invention provides a pharmaceutical composition for administration to a human or an animal comprising a peptide consisting of D-Pro D-Tyr D-Val D-Val or D-Pro D-Tyr D-Val or D-Leu D-Thr D-Val as an active component. This has been found to give great efficacy in lowering serum

10

triglyceride levels.



I



II

Figure 1.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.